

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE S

03 MAY 29 AM 10

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Hoffmann-La Roche Inc.*			
2. Address <input type="checkbox"/> Check if different than previously reported 1300 I Street NW, Suite 520 West, Washington, D.C. 20005-3314			
3. Principal Place of Business (if different from line 2) City: Nutley State/Zip (or Country) New Jersey 07110			
4. Contact Name Candace Sams	Telephone 202-408-0090	E-mail (optional) Candace.Sams@roche.com	5. Senate ID # 18411-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID # 31167000


TYPE OF REPORT 8. Year 2002 Midyear (January 1-June 30) OR Year End (July 1-Dec)9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report ⇨ Termination Date _____

11. No Lobbying

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms
INCOME relating to lobbying activities for this reporting period was:
Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input type="checkbox"/> ⇨ \$ _____ Income (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations
EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>1,451,810</u> Expenses (nearest \$20,000)
14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of
<input type="checkbox"/> Method A. Reporting amounts using LDA definition
<input type="checkbox"/> Method B. Reporting amounts under section 603 Internal Revenue Code
<input type="checkbox"/> Method C. Reporting amounts under section 162 Internal Revenue Code

Signature  _____

Printed Name and Title Michael Eging, Exec. Dir., Public Policy & Federal Gov'n't Affairs

LD-2 (REV. 6/98) *This registration also covers an affiliate company, F. Hoffmann-La Roche Ltd. F

Registrant Name Hoffmann-La Roche Inc. Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

Intellectual Property/ Patent-related issues

Hatch-Waxman Reform

S. 812 - Greater Access to Affordable Pharmaceuticals Act of 2001

17. House(s) of Congress and Federal agencies contacted Check if None

United States House of Representatives
United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
...Brian R. Burns...	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Roche Holding Ltd. - 100% ownership in client.
F. Hoffmann-La Roche Ltd. - Interests similar to those of client.

Signature

Date 4/1/03


Printed Name and Title Michael Eging, Exec. Dir., Public Policy & Federal Govn't Affairs

Form LD-2 (Rev.6/98)

Page

Registrant Name Hoffmann-La Roche Inc. Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each cod information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

S. 2729 - Amend Title XVIII of Social Security Act to provide for a Medicare voluntary prescription drug deliv

S. 2766 - Making appropriations for the Departments of Labor, Health & Human Services & Education

S. 987 - To amend Title XIX of Social Security Act to permit States the option to provide Medicaid coverage

H.R. 2063 - Amend Title XIX of Social Security Act to permit States option to provide Medicaid coverage for with HIV

17. House(s) of Congress and Federal agencies contacted Check if None


United States House of Representatives
United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Brian R. Burns	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Roche Holding Ltd. - 100% ownership in client.
F. Hoffmann-La Roche Ltd. - Interests similar to those of client.

Signature 

Date 4/1/07

[Handwritten signature]
Printed Name and Title Michael Eging, Exec. Dir., Public Policy & Federal Govn't Affairs

Form LD-2 (Rev.6/98)

Page _

Registrant Name Hoffmann-La Roche Inc. Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each piece of information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

H.R. 2887 - Best Pharmaceuticals for Children Act

S. 838 - Best Pharmaceuticals for Children Act

S. 1032 - International Infectious Diseases Control Act

H.R. 2352 - Fair Balance Prescription Drug Advertisement Act

17. House(s) of Congress and Federal agencies contacted

Check if None

United States House of Representatives
United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
..... Brian R. Burns.....
.....
.....
.....
.....
.....
.....

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Roche Holding Ltd. - 100% ownership in client.
F. Hoffmann-La Roche Ltd. - Interests similar to those of client.

Signature 

Date 4/1/03

Printed Name and Title Michael Eging, Exec. Dir., Public Policy & Federal Govn't Affairs

Form LD-2 (Rev.6/98)

Page _

Registrant Name Hoffmann-La Roche Inc. Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

S. 1931 - Amend Title XVIII of Social Security Act to improve patient access to, and utilization of, the colorectal screening benefit under Medicare program.

S. 812 - Greater Access to Affordable Pharmaceuticals Act of 2001

Accutane Issues

17. House(s) of Congress and Federal agencies contacted

Check if None

United States House of Representatives
United States Senate


18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
...Brian R. Burns...
...Michael J. Eging...

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Roche Holding Ltd. - 100% ownership in client.
F. Hoffmann-La Roche Ltd. - Interests similar to those of client.

Signature 

Date 4/1/03

 
Printed Name and Title Michael Eging, Exec. Dir., Public Policy & Federal Gov'n't Affairs

Form LD-2 (Rev.6/98)

Page _

Registrant Name Hoffmann-La Roche Inc. Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

H.R. 1641 - Medicaid Obesity Treatment Act

S. 2625 - Amend Title XVIII of Social Security Act to provide coverage of outpatient prescription drugs under Medicare program

H.R. 4860 - Title XVIII of Social Security Act to provide for voluntary program for prescription drug coverage Medicare.

17. House(s) of Congress and Federal agencies contacted Check if None

United States House of Representatives
United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
..Brian R. Burns..	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Roche Holding Ltd. - 100% ownership in client.
F. Hoffmann-La Roche Ltd. - Interests similar to those of client.

Signature *Michael A. ...*

Date 4/1/03

Printed Name and Title


Michael Eging, Exec. Dir., Public Policy & Federal Gov'n't Affairs

Form LD-2 (Rev.6/98)

Page _

Registrant Name Hoffmann-La Roche Inc. Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

- H.R. 1839 - Immunosuppressive Drug Coverage Act
- S. 880 - Immunosuppressive Drug Coverage Act
- H.R. 3032 - Medicare Coverage of Immunosuppressive Drug Coverage
- S. 1204 - Comprehensive Immunosuppressive Drug Coverage Act

17. House(s) of Congress and Federal agencies contacted Check if None

United States House of Representatives
United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
.....Brian R. Burns.....	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Roche Holding Ltd. - 100% ownership in client.
F. Hoffmann-La Roche Ltd. - Interests similar to those of client.

Signature

Date 4/1/03

Printed Name and Title



Michael Eging, Exec. Dir., Public Policy & Federal Gov'n Affairs

Form LD-2 (Rev. 6/98)

Page _

Registrant Name Hoffmann-La Roche Inc. Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code** information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

S. 358 - Medicare Prescription Drug and Modernization Act

17. House(s) of Congress and Federal agencies contacted

Check if None

United States House of Representatives
United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<u>Brian R. Burns</u>	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Roche Holding Ltd. - 100% ownership in client.
F. Hoffmann-La Roche Ltd. - Interests similar to those of client.

Signature

Date 4/1/03

Printed Name and Title Michael Eging, Exec. Dir., Public Policy & Federal Govn't Affairs

Form LD-2 (Rev. 6/98)

Page 5

Registrant Name Hoffmann-La Roche Inc. Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

Pharmaceutical Regulatory Issues

17. House(s) of Congress and Federal agencies contacted

Check if None

United States House of Representatives
United States Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
..... Brian R. Burns	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Roche Holding Ltd. - 100% ownership in client.
F. Hoffmann-La Roche Ltd. - Interests similar to those of client.

Signature 

Date 4/1/03

Printed Name and Title Michael Eging, Exec. Dir., Public Policy & Federal Gov'n Affairs

Form LD-2 (Rev.6/98)

Page

Registrant Name Hoffmann-La Roche Inc. Client Name Self

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

As noted on the first page, this registration also covers:

F. Hoffmann-La Roche Ltd.

21. Client new principal place of business (if different from line 20)

City Basel State/Zip (or Country) Switzerland

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that no longer pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)



26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities
Previously filed on Form LD-1U			\$10,000

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant or affiliated organization

Signature  Date 4/1/03

Printed Name and Title Michael Eging, Exec. Dir., Public Policy & Federal Gov'n't Affairs

Form LD-2 (Rev. 6/98)

Page 1